Patents Examined by Rachel B Gill
-
Patent number: 11773139Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.Type: GrantFiled: December 14, 2018Date of Patent: October 3, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Stefania Capone, Antonella Folgori, Armin Lahm, Benjamin Wizel
-
Patent number: 11771755Abstract: Nanostructures and nanostructure-based vaccines that display antigens capable of eliciting immune responses to infectious agents such as bacteria, viruses, and pathogens are provided. Some vaccines are useful for preventing or decreasing the severity of infection with an infectious agent, including, for example and without limitation, lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens may be attached to the core of the nanostructure either non-covalently or covalently, including as a fusion protein or by other means. Multimeric antigens may optionally be displayed along a symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.Type: GrantFiled: February 28, 2019Date of Patent: October 3, 2023Assignee: University of WashingtonInventors: Neil King, David Baker, Lance Stewart, Brooke Fiala, Daniel Ellis, Lauren Carter, Rashmi Ravichandran, George Ueda, Jorge Fallas, Una Nattermann
-
Patent number: 11773372Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.Type: GrantFiled: March 25, 2021Date of Patent: October 3, 2023Assignee: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
-
Patent number: 11767346Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (for example, variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: GrantFiled: March 8, 2022Date of Patent: September 26, 2023Assignees: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
-
Patent number: 11759515Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.Type: GrantFiled: March 9, 2021Date of Patent: September 19, 2023Assignee: ARCTURUS THERAPEUTICS, INC.Inventors: Sean Michael Sullivan, Daiki Matsuda, Kiyoshi Tachikawa, Padmanabh Chivukula, Priya Prakash Karmali, Jared Henry Davis, Yanjie Bao
-
Patent number: 11752206Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: GrantFiled: March 15, 2018Date of Patent: September 12, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Patent number: 11746127Abstract: The present invention provides polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. The invention further provides compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.Type: GrantFiled: April 13, 2021Date of Patent: September 5, 2023Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Jonathan Gershoni, Natalia T. Freund
-
Patent number: 11744887Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.Type: GrantFiled: March 9, 2021Date of Patent: September 5, 2023Assignee: ARCTURUS THERAPEUTICS, INC.Inventors: Sean Michael Sullivan, Daiki Matsuda, Kiyoshi Tachikawa, Padmanabh Chivukula, Priya Prakash Karmali, Jared Henry Davis, Yanjie Bao, Amit Sagi
-
Patent number: 11744888Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: December 8, 2021Date of Patent: September 5, 2023Inventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
-
Patent number: 11746335Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: GrantFiled: April 19, 2022Date of Patent: September 5, 2023Assignee: The Government of the United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
-
Patent number: 11732245Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.Type: GrantFiled: July 19, 2021Date of Patent: August 22, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Martin Lock, Mauricio Alvira
-
Patent number: 11730799Abstract: A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer.Type: GrantFiled: June 29, 2021Date of Patent: August 22, 2023Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES GOVERNMENT DEPARTMENT OF VETERANS AFFAIRSInventors: David M. Lubaroff, Delbert L. Harris
-
Patent number: 11730808Abstract: Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.Type: GrantFiled: October 3, 2022Date of Patent: August 22, 2023Assignee: Gilead Sciences, Inc.Inventors: Scott J. Balsitis, Sarah M. Ahmadi-Erber, Timo Schippers, Sarah Schmidt
-
Patent number: 11730807Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.Type: GrantFiled: September 15, 2021Date of Patent: August 22, 2023Assignee: CEVA SANTE ANIMALEInventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
-
Patent number: 11717568Abstract: In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.Type: GrantFiled: November 20, 2020Date of Patent: August 8, 2023Assignee: CITY OF HOPEInventors: Don J. Diamond, Felix Wussow
-
Patent number: 11718835Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.Type: GrantFiled: May 24, 2021Date of Patent: August 8, 2023Assignee: Ths Trustees of the University of PennsylvaniaInventors: Martin Lock, Mauricio Alvira
-
Patent number: 11713449Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.Type: GrantFiled: April 21, 2021Date of Patent: August 1, 2023Assignee: Ths Trustees of the University of PennsylvaniaInventors: Martin Lock, Mauricio Alvira
-
Patent number: 11713450Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.Type: GrantFiled: May 24, 2021Date of Patent: August 1, 2023Assignee: Ths Trustees of the University of PennsylvaniaInventors: Martin Lock, Mauricio Alvira
-
Patent number: 11702673Abstract: Provided herein are methods and compositions useful in the production of recombinant AAV (rAAV) in host producer cells, such as insect cells. In some embodiments, methods, uses and compositions are provided that comprise recombinant VP1 genes comprising modified Kozak sequences to express AAV VP1 proteins in amounts that are useful for producing infective rAAV particles. These infective rAAV particles may comprise a gene of interest.Type: GrantFiled: October 18, 2019Date of Patent: July 18, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Sergei Zolotukhin, Oleksandr Kondratov
-
Patent number: 11692012Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.Type: GrantFiled: March 26, 2021Date of Patent: July 4, 2023Assignee: Oregon Health & Science UniversityInventors: Klaus Frueh, Scott G. Hansen, Jay Nelson, Louis Picker, Patrizia Caposio